Pulmo BioTech Announces Methodology for Phase I Human Trials
Posted on: Monday, 19 May 2008, 12:00 CDT
Pulmo BioTech has reported details of the methodology and purpose of its Phase I human trials with its PulmoBind molecular imaging technology for the diagnosis of pulmonary embolism and pulmonary hypertension.
The study will be a single center, Phase I safety and efficacy study of a single intravenous injection of PulmoBind in human subjects with no history of lung disease. It will be carried out by the Pulmo BioTech subsidiary, PulmoScience Inc.
The study outcomes will be safety - to determine pharmacokinetics and biodistribution of PulmoBind in humans and to perform dosimetric evaluation, and efficacy - to evaluate the ability of PulmoBind to allow lung perfusion imaging in humans. Pulmo BioTech expects this work to be completed by late summer 2008.
Source: Datamonitor
Related Articles
- Pulmo BioTech's Subsidiary Completes Bio-Distribution Studies
- Pulmo BioTech Inc. Completes Bio-Distribution Studies
- Pulmo BioTech Inc. Announces Possibility of MRI Application for PulmoBind
- Pulmo BioTech Announces Details of the Methodology for Its Phase I Human Trials
- Pulmo BioTech Announces an Increase in Its Stake in PulmoScience
- Pulmo BioTech Announces Appointment of Chief Financial Officer
- UM Lures Big Names, Money for Research: The University of Miami Has Embarked on a $1 Billion-Plus Campaign to Make Its Medical School One of the Top Research Institutions in the Country. Can It
- Journey From Hepatocyte Transplantation to Hepatic Stem Cells: A Novel Treatment Strategy for Liver Diseases
- Environmental and Production Benefits Drive Greater Demand for Biotech Crops
User Comments (0)
RSS Feeds